Compare
Charles River Laboratories International, Inc. vs Medpace Holdings, Inc. vs Icon PLC vs Iqvia Holdings Inc.
| Latest fiscal year | Charles River Laboratories International, Inc. CRL | Medpace Holdings, Inc. MEDP | Icon PLC ICLR | Iqvia Holdings Inc. IQV |
|---|---|---|---|---|
| Year ended | 2025-12-27 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.02B | $2.53B | $8.25B | $16.31B |
| Revenue growth (YoY) | -0.9% | +20.0% | +0.8% | +5.9% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | 0.6% | 21.1% | 5.4% | 13.4% |
| Net margin | -3.5% | 17.8% | 2.8% | 8.3% |
| Net income | -$142.16M | $451.12M | $229.34M | $1.36B |
| EPS (Diluted) | -$2.91 | $15.28 | $2.90 | $7.84 |
| Operating cash flow | $737.65M | $713.22M | $1.04B | $2.65B |
| Free cash flow | $518.49M | $681.87M | $861.99M | $2.05B |
| Cash & equivalents | $213.77M | $497.05M | $647.29M | $1.98B |
| Total assets | $7.14B | $1.98B | $16.27B | $29.94B |
| Total liabilities | $3.92B | $1.52B | $7.08B | $23.31B |
| Shareholders' equity | $3.17B | $459.07M | $9.19B | $6.63B |
| Return on year-end equity | -4.5% | 98.3% | 2.5% | 20.5% |
| Shares outstanding | 49.22M | 28.37M | 76.57M | 169.60M |
Revenue, most recent five fiscal years
| Fiscal year | Charles River Laboratories International, Inc. | Medpace Holdings, Inc. | Icon PLC | Iqvia Holdings Inc. |
|---|---|---|---|---|
| Latest | $4.02B Ended 2025-12-27 | $2.53B Ended 2025-12-31 | $8.25B Ended 2025-12-31 | $16.31B Ended 2025-12-31 |
| 1 year earlier | $4.05B Ended 2024-12-28 | $2.11B Ended 2024-12-31 | $8.19B Ended 2024-12-31 | $15.40B Ended 2024-12-31 |
| 2 years earlier | $4.13B Ended 2023-12-30 | $1.89B Ended 2023-12-31 | $8.05B Ended 2023-12-31 | $14.98B Ended 2023-12-31 |
| 3 years earlier | $3.98B Ended 2022-12-31 | $1.46B Ended 2022-12-31 | $7.74B Ended 2022-12-31 | $14.41B Ended 2022-12-31 |
| 4 years earlier | $3.54B Ended 2021-12-25 | $1.14B Ended 2021-12-31 | $5.48B Ended 2021-12-31 | $13.87B Ended 2021-12-31 |